Profile of:

Stefan Siebert

Stefan Siebert is a Professor of Inflammation Medicine and Rheumatology in the School of Infection and Immunity at the University of Glasgow. He also works as an Honorary Consultant Rheumatologist in the Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde where he runs specialist psoriatic arthritis (PsA), complex inflammatory tendinopathy and combined dermatology-gastroenterology-rheumatology clinics. Prof. Siebert leads the PsA and SpA clinical research programme in Glasgow and is the lead on several national and regional investigator-led studies. Research activities include disease pathogenesis, biomarker discovery, comorbidities, routine-data linkage and running observational cohort, experimental medicine and interventional studies. He has published widely in peer-reviewed journals. He is a member of the GRAPPA global steering committee and ASAS, the current Deputy Chair of the NIHR Musculoskeletal Translational Research Collaboration and executive committee member for BRIT-PACT, as well as past Chair of the Versus Arthritis Inflammatory Arthritis Research Advisory Group.

Full name: Stefan Siebert

Current country: United Kingdom

Membership level: Full

Type of membership: Member

Number of publications: 56

EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis (2023)

Predicting a diagnosis of ankylosing spondylitis using primary care health records-A machine learning approach (2023)

Cutaneous lesions in psoriatic arthritis are enriched in chemokine transcriptomic pathways (2023)

Differences in transcriptional changes in psoriasis and psoriatic arthritis skin with immunoglobulin gene enrichment in psoriatic arthritis (2023)

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study (2023)

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials (2023)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study (2023)

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. (2022)

Frailty in rheumatoid arthritis and its relationship with disease activity, hospitalisation and mortality: a longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank. (2022)

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the IMAPA study. (2022)

Challenges in the diagnosis and assessment of Psoriatic Arthritis. (2022)

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. (2022)

Impact of the COVID-19 pandemic on recruitment to clinical research studies in rheumatology. (2022)

Remotely delivered cognitive behavioural and personalised exercise interventions for fatigue severity and impact in inflammatory rheumatic diseases (LIFT): a multicentre, randomised, controlled, open-label, parallel-group trial (2022)

Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy (2022)

The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis (2022)

Long-term Outcomes Following Severe COVID-19 Infection: A Multicenter Cohort Study of Family Member Outcomes. (2021)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. (2021)

Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé (2021)

Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. (2021)

The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions (2021)

Estimating Cardiovascular Impacts of Drugs for Psoriatic Disease: A Long Way to Go (2021)

Does Age Matter in Psoriatic Arthritis? A Narrative Review (2021)

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study (2021)

TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis (2021)

TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors (2021)

The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register (2021)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials (2021)

Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial (2021)

Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity – a cross-sectional study (2021)

Examining the Relationship Between Rheumatoid Arthritis, Multimorbidity, and Adverse Health-Related Outcomes: A Systematic Review (2021)

Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé (2021)

Does Age Matter in Psoriatic Arthritis? A Narrative Review (2021)

Comorbidity burden in axial spondyloarthritis: a cluster analysis. (2020)

Physical activity and sedentary behaviour and their associations with clinical measures in axial spondyloarthritis. (2020)

Treatment strategies in axial spondyloarthritis: what, when and how? (2020)

The IL-23/IL-17A Axis in Spondyloarthritis: Therapeutics Informing Pathogenesis? (2020)

Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis (2020)

Identifying frailty in trials: an analysis of individual participant data from trials of novel pharmacological interventions (2020)

Classification criteria: time for a rethink? (2020)

T cells and cytokines in inflamed psoriatic skin. Who’s in charge? (2020)

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (2020)

JAK inhibitors and infections risk: focus on herpes zoster (2020)

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? (2019)

Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. (2019)

AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). (2019)

Non-radiographic axial spondyloarthritis (nr-axSpA) – Advances in classification, imaging and therapy. (2019)

Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review. (2019)

Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank (2019)

Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials (2019)

Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions (2019)

Influence of co-morbid fibromyalgia on disease activity measures and response to TNF inhibitors in axial spondyloarthritis: results from a UK national register. (2018)

The co-occurrence and characteristics of patients with axial spondyloarthritis who meet criteria for fibromyalgia: Results from a UK national register (BSRBR-AS). (2017)

BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. (2017)

Ankylosing Spondylitis Patients Display Altered Dendritic Cell and T Cell Populations That Implicate Pathogenic Roles for the IL-23 Cytokine Axis and Intestinal Inflammation. (2016)

Modelling health utility values in Ankylosing Spondylitis: Comparisons of direct and indirect methods. (2015)